Therefore, a better understanding of IL-1β levels and autophagy status in AD brains according to the stage of the disease would allow improved targeting of anti-IL-1β and pro-autophagic therapies to reduce cognitive decline. This evidence concerns the gene IL1B and Alzheimer disease.